Contineum Therapeutics (CTNM) Retained Earnings (2023 - 2025)
Historic Retained Earnings for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to -$162.2 million.
- Contineum Therapeutics' Retained Earnings fell 5774.87% to -$162.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.2 million, marking a year-over-year decrease of 5774.87%. This contributed to the annual value of -$117.4 million for FY2024, which is 5623.6% down from last year.
- As of Q3 2025, Contineum Therapeutics' Retained Earnings stood at -$162.2 million, which was down 5774.87% from -$149.4 million recorded in Q2 2025.
- Contineum Therapeutics' 5-year Retained Earnings high stood at -$75.1 million for Q4 2023, and its period low was -$162.2 million during Q3 2025.
- In the last 3 years, Contineum Therapeutics' Retained Earnings had a median value of -$110.1 million in 2024 and averaged -$114.6 million.
- In the last 5 years, Contineum Therapeutics' Retained Earnings tumbled by 5623.6% in 2024 and then tumbled by 6137.37% in 2025.
- Over the past 3 years, Contineum Therapeutics' Retained Earnings (Quarter) stood at -$75.1 million in 2023, then plummeted by 56.24% to -$117.4 million in 2024, then crashed by 38.18% to -$162.2 million in 2025.
- Its Retained Earnings stands at -$162.2 million for Q3 2025, versus -$149.4 million for Q2 2025 and -$133.4 million for Q1 2025.